Gastrointestinal stromal tumor natural history: Difference between revisions
Akshun Kalia (talk | contribs) |
Akshun Kalia (talk | contribs) |
||
| Line 24: | Line 24: | ||
*Depending on the extent of the | *Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. | ||
*Prognosis of GIST depends upon size, location, spread and mitotic rate of the tumor. | |||
**Patients with gastric GIST have been reported to have better outlook as compared to patients with extragastric GIST. | |||
**Patients with localized primary disease have a average survival period of 5 years. | |||
**Patients with malignant lesions and metastasis have an average survival period of 1-2 years. | |||
**Patients with mitotic rate of >10 per 50 HPF have an average survival period of 1.5-2 years | |||
**Patients with mitotic rate <10 per HPF have an average survival period of 8 years. | |||
'However, the prognosis is generally regarded as poor/good/excellent. | |||
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | *The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | ||
*[Subtype of disease/malignancy] is associated with the most favorable prognosis. | *[Subtype of disease/malignancy] is associated with the most favorable prognosis. | ||
Revision as of 21:18, 7 December 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
|
Gastrointestinal stromal tumor Microchapters |
|
Differentiating Gastrointestinal stromal tumor from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Gastrointestinal stromal tumor natural history On the Web |
|
American Roentgen Ray Society Images of Gastrointestinal stromal tumor natural history |
|
Directions to Hospitals Treating Gastrointestinal stromal tumor |
|
Risk calculators and risk factors for Gastrointestinal stromal tumor natural history |
Overview
Most common site of involvement of GIST is stomach(70%).
Natural history
Common sites of involvement include:
- Stomach: 70%
- Small intestine: 20-25%
- Anorectum: 7%
- Oesophagus
GISTs occur not only anywhere along the gastrointestinal tract, but also in the mesentery, omentum and retroperitoneum, which is called extra-gastrointestinal GISTs. Metastatic lesions may also be seen in cases of malignant extra-gastrointestinal GISTs
Prognosis
At the time of clinical presentation, the prognosis appears to be influenced by genetic events other than kinase mutations, although a particular kinase mutation may help to define the initial clinical course of a GIST. Based on retrospective studies from time periods that predated the clinical use of kinase inhibitors, current recommendations for assessing the risk of progression for a newly diagnosed primary GIST rely on three parameters:
- Mitotic index (mitoses per 50 high-power fields)
- Tumor size
- Tumor location[1]
- Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary.
- Prognosis of GIST depends upon size, location, spread and mitotic rate of the tumor.
- Patients with gastric GIST have been reported to have better outlook as compared to patients with extragastric GIST.
- Patients with localized primary disease have a average survival period of 5 years.
- Patients with malignant lesions and metastasis have an average survival period of 1-2 years.
- Patients with mitotic rate of >10 per 50 HPF have an average survival period of 1.5-2 years
- Patients with mitotic rate <10 per HPF have an average survival period of 8 years.
'However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.